Short Interest in Algernon Pharmaceuticals Inc. (OTCMKTS:AGNPF) Rises By 50.6%

Algernon Pharmaceuticals Inc. (OTCMKTS:AGNPF) saw a large increase in short interest in the month of January. As of January 30th, there was short interest totaling 27,159 shares, an increase of 50.6% from the January 15th total of 18,035 shares. Based on an average daily trading volume, of 12,513 shares, the short-interest ratio is currently 2.2 days. Based on an average daily trading volume, of 12,513 shares, the short-interest ratio is currently 2.2 days.

Algernon Pharmaceuticals Price Performance

Shares of AGNPF stock opened at $0.04 on Friday. The company’s fifty day simple moving average is $0.05 and its two-hundred day simple moving average is $0.05. Algernon Pharmaceuticals has a 1 year low of $0.03 and a 1 year high of $0.08.

Algernon Pharmaceuticals Company Profile

Algernon Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel, small-molecule therapeutics. The company’s primary strategy centers on repurposing known compounds with established safety profiles to address unmet medical needs, particularly in the realms of pulmonary fibrosis, acute lung injury and central nervous system (CNS) disorders. By leveraging existing pharmacology data, Algernon aims to accelerate its development timelines while managing costs and risks typically associated with early-stage drug discovery.

The lead asset in Algernon’s pipeline is NP-120 (ifenprodil), an orally available small molecule being investigated for idiopathic pulmonary fibrosis (IPF).